AnHeart Therapeutics ’ Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial
Taletrectinib also shrank tumors in 57 percent of people with ROS1-positive NSCLC who had previously been treated with a ROS1 TKI in the trial
Taletrectinib continues to be generally well tolerated with low incidence of neurological adverse...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Brain | Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Pharmaceuticals